Sandoz's Biopharmaceuticals Sales Growth Justifies Development Work
Pharma & Healthcare / Germany / Fri 27 Jul, 2018
Key View: Sandoz's overall Q218 sales have been hampered by US sales, which continue to be troublesome for Sandoz; with several consecutive quarters of declines, US sales are now at their lowest point since before Q114. Biopharmaceuticals sales are proving to be an increasingly bright spot for Sandoz. Whilst they remain a small part of total